These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29326124)

  • 1. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results.
    Koreth J; Kim HT; Lange PB; Poryanda SJ; Reynolds CG; Rai SC; Armand P; Cutler CS; Ho VT; Glotzbecker B; Yusuf R; Nikiforow S; Chen YB; Dey B; McMasters M; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Haematologica; 2018 Mar; 103(3):522-530. PubMed ID: 29326124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
    Bolaños-Meade J; Reshef R; Fraser R; Fei M; Abhyankar S; Al-Kadhimi Z; Alousi AM; Antin JH; Arai S; Bickett K; Chen YB; Damon LE; Efebera YA; Geller NL; Giralt SA; Hari P; Holtan SG; Horowitz MM; Jacobsohn DA; Jones RJ; Liesveld JL; Logan BR; MacMillan ML; Mielcarek M; Noel P; Pidala J; Porter DL; Pusic I; Sobecks R; Solomon SR; Weisdorf DJ; Wu J; Pasquini MC; Koreth J
    Lancet Haematol; 2019 Mar; 6(3):e132-e143. PubMed ID: 30824040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.
    Ceberio I; Devlin SM; Sauter C; Barker JN; Castro-Malaspina H; Giralt S; Ponce DM; Lechner L; Maloy MA; Goldberg JD; Perales MA
    Leuk Lymphoma; 2015 Mar; 56(3):663-70. PubMed ID: 24913499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
    Perez-Simón JA; Martino R; Parody R; Cabrero M; Lopez-Corral L; Valcarcel D; Martinez C; Solano C; Vazquez L; Márquez-Malaver FJ; Sierra J; Caballero D
    Haematologica; 2013 Apr; 98(4):526-32. PubMed ID: 23065527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
    Bolaños-Meade J; Hamadani M; Wu J; Al Malki MM; Martens MJ; Runaas L; Elmariah H; Rezvani AR; Gooptu M; Larkin KT; Shaffer BC; El Jurdi N; Loren AW; Solh M; Hall AC; Alousi AM; Jamy OH; Perales MA; Yao JM; Applegate K; Bhatt AS; Kean LS; Efebera YA; Reshef R; Clark W; DiFronzo NL; Leifer E; Horowitz MM; Jones RJ; Holtan SG;
    N Engl J Med; 2023 Jun; 388(25):2338-2348. PubMed ID: 37342922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
    Törlén J; Ringdén O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itälä-Remes M; Remberger M; Mattsson J
    Haematologica; 2016 Nov; 101(11):1417-1425. PubMed ID: 27662016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-
    Drobyski WR; Szabo A; Zhu F; Keever-Taylor C; Hebert KM; Dunn R; Yim S; Johnson B; D'Souza A; Eapen M; Fenske TS; Hari P; Hamadani M; Horowitz MM; Rizzo JD; Saber W; Shah N; Shaw B; Pasquini M
    Haematologica; 2018 Apr; 103(4):717-727. PubMed ID: 29351985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
    Koreth J; Stevenson KE; Kim HT; Garcia M; Ho VT; Armand P; Cutler C; Ritz J; Antin JH; Soiffer RJ; Alyea EP
    Blood; 2009 Oct; 114(18):3956-9. PubMed ID: 19713456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
    Koreth J; Stevenson KE; Kim HT; McDonough SM; Bindra B; Armand P; Ho VT; Cutler C; Blazar BR; Antin JH; Soiffer RJ; Ritz J; Alyea EP
    J Clin Oncol; 2012 Sep; 30(26):3202-8. PubMed ID: 22869883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients.
    Nakane T; Okamura H; Tagaito Y; Koh S; Yoshimura T; Makuuchi Y; Nanno S; Nakamae M; Hirose A; Nakashima Y; Koh H; Hino M; Nakamae H
    Int J Hematol; 2019 Dec; 110(6):736-742. PubMed ID: 31560116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.
    Pidala J; Kim J; Alsina M; Ayala E; Betts BC; Fernandez HF; Field T; Jim H; Kharfan-Dabaja MA; Locke FL; Mishra A; Nishihori T; Ochoa-Bayona L; Perez L; Riches M; Anasetti C
    Haematologica; 2015 Jul; 100(7):970-7. PubMed ID: 25840599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.
    Al-Kadhimi Z; Gul Z; Rodriguez R; Chen W; Smith D; Mitchell A; Abidi M; Ayash L; Deol A; Lum L; Forman S; Ratanatharathorn V; Uberti J
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1734-44. PubMed ID: 22710143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.
    Kornblit B; Maloney DG; Storer BE; Maris MB; Vindeløv L; Hari P; Langston AA; Pulsipher MA; Bethge WA; Chauncey TR; Lange T; Petersen FB; Hübel K; Woolfrey AE; Flowers ME; Storb R; Sandmaier BM
    Haematologica; 2014 Oct; 99(10):1624-31. PubMed ID: 25085357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
    Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.
    Pidala J; Kim J; Jim H; Kharfan-Dabaja MA; Nishihori T; Fernandez HF; Tomblyn M; Perez L; Perkins J; Xu M; Janssen WE; Veerapathran A; Betts BC; Locke FL; Ayala E; Field T; Ochoa L; Alsina M; Anasetti C
    Haematologica; 2012 Dec; 97(12):1882-9. PubMed ID: 22689677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT.
    Choi SW; Braun T; Henig I; Gatza E; Magenau J; Parkin B; Pawarode A; Riwes M; Yanik G; Dinarello CA; Reddy P
    Blood; 2017 Oct; 130(15):1760-1767. PubMed ID: 28784598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.